Table 1.
Studies | Animal Model (n) | Location of Implant Placement | Follow-Up | Analysis Methods | Conclusions |
---|---|---|---|---|---|
Zhang et al. [19] | Beagle dog model (3) |
Mandible (premolars and molar area) | 4 weeks |
|
The SLA-Ta (Tantalum) surface showed excellent antibacterial activity against Porphyromonas gingivalis and Fusobacterium nucleatum involved in peri- implant infections. |
Zhou et al. [20] | New Zealand rabbit model (24) |
Femoral shafts area | 8 weeks |
|
The incorporation of Strontium (Sr) induces a better osseointegration, but it did not affect its angiogenic and antibacterial capabilities. |
Ding et al. [21] | Wild mice model (20) |
The upper first right molar area | 8 weeks |
|
The doxycycline (DC)-treated Hydroxyapatite (HA)-coated implant surface promotes bone apposition around the implant. |
Nie et al. [22] | Rat model (36) |
Femur | 3 weeks |
|
The bacitracin (BC) on the Ti surface demonstrated potential prophylaxis against Ti implant-associated infection. Further, the BC-coated Ti showed potential towards osteoinductvity in a rat model. |
Lee et al. [23] | Hound Labrador dogs (12) |
Mandibular premolar area | 8 weeks |
|
Human bone morphogenetic protein- 2 (rhBMP-2)-coated tita- nium porous oxide implants induce significant bone formation. |
Susin et al. [24] | Hound Labrador dogs (6) |
Mandibular premolar area | 8 weeks |
|
rhBMP-7 coated onto Ti porous-oxide surface implants induces clinically relevant local bone formation including osseointegration and vertical augmentation of the alveolar ridge. |
BV, bone volume; BMD, bone mineral density; Tb.Th, trabecular thickness; Tb.N, trabecular number; BIC, bone to implant contact; Ti, titanium; Ta, tantalum; Sr, strontium; BA, bone area; DC, doxycycline; BC, bacitracin; HA, hydroxyapatite; rhBMP, human bone morphogenetic protein.